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Research in context 
Evidence before this study 
There is limited literature available on the prevalence and impact of comorbidities on mortality 
and other disease-related outcomes in bronchiectasis. 
Added value of this study 
In this study, we have confirmed that patients with bronchiectasis are frequently afflicted by 
comorbidities which may drive disease, many of which confer an independent risk of death and 
may be missed unless specifically searched for. We have developed a quantitative risk 
stratification tool, the Bronchiectasis Aetiology and Comorbidity Index (BACI) from a large 
multicentre derivation cohort of 986 bronchiectasis patients with validation in two independent 
cohorts with 5 and 19 years of follow-up. Our data demonstrate that measurements of 
comorbidities as captured by the BACI improve the prognostic accuracy for mortality, when 
used independently, or in conjunction with the Bronchiectasis Severity Index (BSI), to identify 
patients at risk of future mortality, hospitalisations and exacerbations across different healthcare 
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systems. The BACI also carries independent prognostic value relating to future disease 
outcomes including future exacerbations, hospitalization for severe exacerbations and 
Pseudomonas aeruginosa infection. The BACI performs significantly better than any 
comorbidity scores currently available including the Charlson Comorbidity index and a simple 
comorbidity count suggesting that a disease-specific comorbidity score is useful in this patient 
population.  
 
Implications of all the available evidence 
The BACI may be a useful clinical predictive tool, when used independently, or in conjunction 
with the BSI, to risk-stratify patients and assist clinical decision making and personalised 
medicines approaches in bronchiectasis. The identification of “risky” comorbidities that may 
lead to stricter follow up of these patients may provide a practical viewpoint for clinicians 
beyond the BACI score calculation. Future interventions and treatment approaches should 
consider multiple comorbidities in these patients in order to maximise outcome and reduce the 
illness burden associated with this disease. 
 
140 character summary: The Bronchiectasis Aetiology and Comorbidity Index (BACI) 
identifies patients at risk of future mortality, hospitalisations, exacerbations and other 
outcomes. 
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Abstract: (250 words) 
Background: Patients with bronchiectasis often suffer from concurrent comorbidities but their 
nature, prevalence and impact on disease severity and outcome is poorly understood. We aimed 
to evaluate comorbidities in bronchiectasis patients and determine their prognostic value on 
disease severity and mortality. 
Methods: An observational cohort analysis of 986 bronchiectasis patients across four European 
centres was performed for score derivation. Comorbidity diagnoses were based on standardised 
definitions obtained on full review of hard copy and electronic records, prescriptions and 
investigator definitions. Weibull parametric survival analysis was used to model the prediction 
of 5-year mortality to construct the Bronchiectasis Aetiology Comorbidity Index (BACI). We 
tested the BACI as a predictor of outcomes and explored whether the BACI added further 
prognostic information when used alongside the Bronchiectasis Severity Index (BSI). 
Findings: Median number of comorbidities per patient was 4 (IQR 2-6), range 0-20. Thirteen 
comorbidities independently predicting mortality were integrated into the BACI. The overall 
hazard ratio for death conferred by a one point increase in the BACI was 1.18 (1.14-1.23), 
p<0.0001. The BACI predicted 5-year mortality, hospitalisations, exacerbations and health-
related quality of life across all BSI risk strata (p<0.0001). When used in conjunction with the 
BSI, the combined model was superior to either model alone. The BACI was validated in two 
independent international cohorts. 
Interpretation: Multimorbidity is frequent in bronchiectasis and can negatively influence 
survival. The BACI complements the BSI in assessing mortality and disease outcomes in 
patients with bronchiectasis. 
Funding:  1. European Bronchiectasis Network (EMBARC).2. Health Research Board Ireland. 
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Introduction 
Bronchiectasis is a chronic airway disease showing an increasing prevalence over the past decade 
with an associated growing morbidity and mortality worldwide.1 As a complex multi-component 
disease, bronchiectasis is characterised by chronic systemic inflammation that frequently co-exists 
with comorbidities, which may be causative, synergistic, or coincidental, depending on the manner 
in which they interact.2 
In addition to known aetiologies of bronchiectasis, several other diseases may occur at any stage 
of bronchiectasis and are likely major contributors to increased hospitalisations, healthcare 
utilisation and socioeconomic costs.3 These include cardiovascular disorders, gastro-oesophageal 
reflux disease (GORD), psychological illnesses, pulmonary hypertension, cognitive impairment, 
and lung, oesophageal and hematological malignancies.4-12 A few studies have explored 
bronchiectasis-related comorbidities and suggest that, compared with age and sex-matched 
controls, some comorbidities are more likely to coexist with bronchiectasis4-12 with a relevant 
impact on different outcomes, such as exercise capacity,4 exacerbation  frequency,6,8 lung 
function,7,11 health-related quality of life,6,8,9,11 healthcare utilisation,8 and mortality.10,12 Few 
studies have systematically evaluated the prevalence and role of comorbidities in bronchiectasis; 
several were performed in single centres with small patient numbers4-6,10,11 or utilised retrospective 
databases or cross-sectional designs7-9,12 limiting the applicability of their findings. However, none 
have systematically evaluated how comorbidities impact on prognosis in a prospective study. 
It is suggested that individual comorbidities and aetiologies of bronchiectasis, such as chronic 
obstructive pulmonary disease (COPD) and rheumatoid arthritis (RA), confer an increased severity 
and mortality compared to other aetiologies despite targeted treatment of underlying conditions.13,14 
Recent literature has also shown that in approximately 30-40% of patients with bronchiectasis, the 
primary cause of death is attributed to non-respiratory disease.15 However, current guidelines fail 
to provide clear recommendations on how comorbidities should be identified, assessed and treated 
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within the context of bronchiectasis. Neither of the two prognostic scoring indices recently 
developed to estimate mortality in patients with bronchiectasis (the bronchiectasis severity index –
BSI- and the FACED score-see online supplement for calculation of scores) were planned to 
systematically evaluate the prevalence and role of comorbidities.16,17 
In view of this lack of data, we designed a study which aimed to determine not only the prevalence 
of individual comorbidities in bronchiectasis patients but also the strength of association between 
the number and nature of comorbidities and risk of death over time. We further aimed to develop 
a disease-specific comorbidity index and explore if this could provide additional prognostic 
information to that provided by the BSI. 
Our hypothesis was that multiple comorbidities would be a common finding acroos national 
cohorts, that these would contribute significantly to mortality and that it was practicable to apply a 
standardized assessment to assess the role of comorbities in the mortality of patients with 
bronchiectasis. 
 
Methods 
Data collection 
This study included data from four databases of prospectively enrolled outpatients with 
bronchiectasis in Dundee (UK), Galway (Ireland), Leuven (Belgium) and Monza (Italy). 
Consecutive patients aged ≥18 years were enrolled on the basis of a radiological diagnosis made 
on high-resolution computed tomography (HRCT) and a clinical history consistent with 
bronchiectasis. Patients with cystic fibrosis or traction bronchiectasis due to pulmonary fibrosis 
were excluded in all four cohorts. Data from each cohort was collected independently following 
individual ethics approval and collated for statistical analysis. Standardised assessment and 
diagnostic work-up according to the 2010 British Thoracic Society (BTS) guidelines was 
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performed at each site as detailed in the online supplement. Enrolment into the study required that 
all variables required to calculate clinical prediction scores and the key relevant outcomes of 
mortality, hospitalisations and exacerbations on follow-up were available. Exacerbations and 
hospitalisations were defined according to BTS guidelines, and mortality, evaluated at the end of 
the 5-year follow-up period, was confirmed in 100% of participants.18 This cohort is entirely 
independent from the cohorts used to derive the BSI or FACED scores.16,17 
 
Comorbidities 
All comorbidity diagnoses were systematically recorded according to standardised definitions and 
were retrospectively obtained on full review of hard copy or electronic records, patients’ 
prescriptions and review of confirmatory tests where available. The 19 conditions included in the 
Charlson Comorbidity Index (CCI) were included in data collection plus any other identified 
comorbidity.19 Conditions that had completely resolved, e.g. pneumonia, were excluded. Objective 
confirmation of diagnoses was sought in each case where possible. Self-reported diagnoses 
consisted of GORD, depression and anxiety as per standard practice internationally. Further details 
of comorbidity assessment are available in the online supplement. 
 
Statistical Analysis and Derivation of Clinical Prediction Tool 
Continuous data are presented as mean and standard deviation (SD) or median and interquartile 
range (IQR) where appropriate, and categorical data as frequencies and percentages. The Mann 
Whitney U and chi-squared test were used for comparison of numerical and categorical data, 
respectively. For comparisons of more than two groups, one-way analysis of variance or the 
Kruskal-Wallis test were used as appropriate. Weibull parametric survival analysis was used to 
model the prediction of 5-year mortality. Three candidate comorbidity scores were considered and 
9 
 
compared to the CCI, BSI and FACED scores: (a) The Comorbidity count - a simple sum of the 
number of comorbidities per individual patient; (b) The Bronchiectasis Comorbidity Index (BCI) - 
a weighted comorbidity score without those conditions regarded as potential underlying aetiologies 
of bronchiectasis; (c) The Bronchiectasis Aetiology Comorbidity Index (BACI) - a weighted 
comorbidity score including conditions regarded as underlying aetiologies. 
Based on Peduzzi’s modelling, a maximum of 13 variables could be incorporated into the 
multivariable models in order to comply with statistical norms based on the number of outcomes 
in our cohort.20 Comorbidities with <1% prevalence or those with significant collinearity were 
excluded. Variables were included in the model using a backward stepwise approach requiring a 
p<0.2 for retention in the model. All models were adjusted for age and gender. These variables 
were then formed into prediction tools using the rounded averaged β-coefficient to award “points” 
for each variable as previously described.16 The sum of the points intends to capture the individual 
or combination of diseases affecting each patient. The performance of the resulting models for 
mortality was assessed using the area under the receiver operator characteristic curve (AUC) with 
the exception of the UK validation cohort which had a much longer follow up of 20 years, whereby 
Kaplan-Meier analysis was performed to avoid favoring fixed effects at the expense of modifiable 
risk factors that may increase short-term risk but not necessarily guarantee long-term risk. We 
subsequently tested the predictive ability of the optimal model to determine future disease 
outcomes using Spearman’s rho correlation and explored if it could add further prognostic 
information when used alongside the BSI and FACED mortality index. Some endpoints, such as 
quality of life, were only available in 2 cohorts (Dundee and Monza). Such analyses were only 
conducted in patients with available data – no imputation or other methods of handling missing 
data were used. For all analyses, p< 0.05 was considered statistically significant. All analyses were 
performed using SPSS Version 21 (SPSS, Chicago, IL, USA) for Windows platform and Graph 
Pad Prism Version 5 (Graph Pad Software, Inc. San Diego, CA, USA). The reporting of this study 
conforms to STROBE and TRIPOD recommendations.21 22 
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Validation cohorts 
The derived index was subsequently validated in two independent cohorts. One was a historical 
cohort of patients recruited for the validation of the SGRQ in bronchiectasis.15 This cohort was 
selected as a prospective study with the longest duration of follow-up available in the literature to 
date, where data on comorbidities was systematically collected. The other validation cohort 
consisted of prospectively recruited bronchiectasis patients in Serbia in Eastern Europe, enabling 
further assessment of the generalisability of the score. 
 
Role of the funding source 
The funding source had no role in study design, data collection, analysis or interpretation or in the 
writing of the report. The corresponding and lead senior authors had full access to all of the data 
and the final responsibility to submit for publication." 
 
Results 
Characteristics of the cohort and comorbidities  
The demographic and baseline characteristics of the 986 patients included in the analysis are 
summarised in Table 1 and are consistent with other published series in terms of older age, female 
predominance and bacterial colonisation rates. The cohort consisted primarily of Caucasian 
females with a median FEV1% predicted of 75% (54-95) and a median FEV1/FVC% predicted of 
70% (59-79) demonstrating moderate airflow limitation. The median BSI was 6 (4-10) and all BSI 
tertiles (mild, moderate and severe) were evenly represented. Mortality, n (%) at 1, 2, 3 and 5 years 
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of follow-up were 37 (3.7), 47 (4.8), 85 (8.6) and 122 (12.4), respectively. No patients received 
lung transplantation during follow-up.  
A total of 81 comorbidities were reported in this cohort. The median (IQR) number of 
comorbidities was 4 (2-6) per subject for the whole cohort with a range of 0-20; males had 
significantly more co-morbidities than females, median 4 (2-6) for males and 3 (2-5) for females, 
p=0.005. . The median number of comorbidities was higher for non-survivors compared with 
survivors [6 (4-9) vs 3 (2-5) respectively, p<0.0001. A significant association was also observed 
between the median number of comorbidities and the BSI score (low risk: 3; intermediate risk: 3; 
high risk: 4; p<0.0001). 
The distribution of the most prevalent (>1%) and significant comorbidities is shown in Figure 1. 
There is a heavy tailed distribution, ranging from 34% to less than 1%. 26 comorbidities had a 
significantly higher prevalence in non-survivors compared with survivors (the majority are shown 
here by the presence of asterisks in Figure 1 with full details in Table S1 in the online supplement).  
 
Comorbidity scores 
The Comorbidity Count 
In its simplest form, the comorbidity count, i.e. the sum of the number of comorbidities per patient, 
was significantly associated with mortality, with a hazard ratio (HR) of 1.17, 95% CI 1.12-1.23 on 
univariate analysis, suggesting that an increase of 1 comorbidity in the count equates to a 17% 
increase in mortality. When adjusted for BSI, the HR (95% CI) was still significant at 1.13 (1.08-
1.18). 
The Bronchiectasis Aetiology Comorbidity Index (BACI) 
The comorbidities included in the BACI are shown in Table 2. COPD, connective tissue disease, 
inflammatory bowel disease and asthma were all included in the final model predicting mortality 
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and are recognised aetiologies of bronchiectasis that may be associated with poorer outcomes. 
Overall, the HR (95% CI) for death conferred by a one-point increase in the BACI score was 1.18 
(1.14-1.23), p<0.0001. Interestingly, this is higher than the adjusted HR for the BSI of 1.10 (1.06-
1.14), p<0.0001 suggesting that the BACI has independent prognostic value comparable to the BSI. 
The Bronchiectasis Comorbidity Index (BCI) 
As a sensitivity analysis, we evaluated a model excluding the above conditions thought to be 
associated with bronchiectasis, producing similar results (Table S2 in online supplement). The HR 
for the BCI was comparable at 1.17 (1.12-1.23), confirming the importance of comorbidities in 
bronchiectasis prognosis. 
 
Comparison of comorbidity scores to predict 5-year mortality 
Comparative AUC (95% CI) scores for the BACI and BCI with the widely validated BSI can be 
seen in figure 2(a). The BACI has the highest overall predictive ability in this cohort to predict 5-
year survival with an AUC score of 0.79 (0.75-0.83) versus 0.74 (0.69-0.78) for the BCI, 0.78 
(0.73-0.84) for the BSI and 0.71 (0.66-0.75) for the FACED score, respectively. The CC and CCI 
(figure 2(b)) showed AUC scores of 0.72 (0.67-0.76) and 0.74 (0.69-0.78) respectively, which were 
inferior to the BACI (p=0.0001 on comparing AUC values), suggesting that a specific comorbidity 
index for bronchiectasis is appropriate.   
The BACI performed consistently better than all scores in predicting 2, 3 and 5-year mortality in 
this cohort, with AUC scores of 0.75, 0.76 and 0.79 respectively, indicating that the score works 
similarly for annual prediction as for longer term prediction. 
The AUC was used to identify the level of the BACI with the greatest predictive value for death in 
patients with bronchiectasis. Patients were classified into tertiles designated no high-risk 
comorbidities (for patients with a score of zero, n=402), intermediate risk comorbidities (for 
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patients with >1 and <6 points, n=398) and high-risk comorbidities (for patients with a score ≥ 6 
points, n=186). The relationship between these risk groups and mortality and morbidity are shown 
in Figure 3.  
The sensitivity and specificity values for the BACI, BCI and the BSI are shown in table 3.  
 
The BACI, BSI and mortality 
Comparable with previous studies, the BSI was a significant predictor of death in patients with 
bronchiectasis. To demonstrate the predictive contribution of the BACI to the BSI, Kaplan-Meier 
survival curves of the BACI groups stratified according to BSI severity are shown in Figure 4. All 
between group comparisons were statistically significant at p<0.001. 
 
A prediction model incorporating both the BSI and the BACI was superior to either model alone 
for the prediction of 5-year mortality in this cohort with an AUC (95% CI) of 0.83 (0.79-0.87). 
 
The BACI and other disease outcomes 
Significant correlations of the BACI with a number of baseline demographic variables and 
important clinical outcomes were noted. The BACI correlated with both the BSI and FACED 
disease severity scores as well as lung function, radiological scores, dyspnoea scores, prior 
exacerbations and hospitalisations. Of note, it also predicts subsequent exacerbations and 
hospitalisations on follow-up and is independently correlated with Pseudomonas aeruginosa 
colonisation, offering further predictive potential in the clinical setting and suggesting that co-
morbidities directly influence pulmonary outcomes (Table 4).  
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Independent validation cohorts 
The Serbian validation cohort consisted of 113 patients, mean age 62 years (13) at diagnosis, 70% 
female. 5-year mortality was 17.7%. The AUC for predicting 5 year mortality in the Serbian cohort 
was 0.74 (95% CI 0.63-0.86). The UK validation cohort included 88 patients, mean age (SD) 51 
years (12.1) at enrolment, with 57% female. Mortality at 20 years was 40.9%. The BACI was 
significantly associated with mortality at 20 years, p=0.004 (Kaplan-Meier), (figure 5). 
 
Discussion  
The present study is the first multicentre international observational study to systematically 
describe the prevalence and associations of comorbidities on mortality in patients with 
bronchiectasis. A new disease-specific comorbidity risk index (the BACI) was derived to help 
predict which patients with bronchiectasis are at increased risk of death independently of their 
baseline physiological state. The BACI accurately stratified the risk of mortality and 
hospitalisations whilst demonstrating that comorbidities contribute to exacerbation frequency and 
impaired quality of life.  The BACI may be a useful clinical predictive tool, when used 
independently, or in conjunction with the BSI, to risk-stratify patients and assist clinical decision 
making and personalised medicines approaches in bronchiectasis. 
This is one of the largest cohort studies performed to date in bronchiectasis and is in keeping with 
other studies in bronchiectasis and other comorbidity derivation tools. In bronchiectasis, the BSI 
and FACED consisted of 608 and 397 patients respectively in their derivation cohorts.16,17 The 
Charlson Comorbidity Index, which is perhaps one of the most widely utilised comorbidity 
assessment tools worldwide, consisted of 604 patients in their derivation cohort.19 Therefore, our 
sample size of 986 is more than adequate to derive this score. 
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Most respiratory diseases have disease-specific assessment tools, designed to identify patients at 
high risk of complications who may benefit from early treatment intensification. There is 
accumulating evidence that patients with bronchiectasis, similar to COPD, are prone to develop 
other important diseases, over and above what can be expected in an age and sex-matched general 
population, including cardiovascular disease, pulmonary hypertension and lung cancer, among 
others.4,10,12 With bronchiectasis, there is a “double hit” as many patients may already have an 
underlying aetiology that led to the development of bronchiectasis, potentially increasing the 
likelihood of developing further complications. For example, patients with rheumatoid arthritis and 
bronchiectasis may be receiving immunosuppressive treatments that increase the likelihood of 
complications, or patients with COPD-associated bronchiectasis may be at increased risk of lung 
cancer due to synergistic effects of airway inflammation and smoking.23 
Systemic inflammation has been proposed as a potential explanation of the mechanistic pathway 
relating bronchiectasis with its comorbidities, in part due to the ageing process, which is strongly 
associated with an increased likelihood of developing multiple chronic conditions.24 The 
association between biomarkers of systemic inflammation and outcomes in bronchiectasis, 
including comorbidities, has not been well documented. In COPD, studies have demonstrated that 
elevated baseline inflammatory markers are associated with an increased risk of myocardial 
infarction, diabetes mellitus, lung cancer and pneumonia with the “inflamed comorbids” having 
the lowest survival in COPD populations.25 Addressing this knowledge gap may allow us to 
identify pathway-specific treatment targets that could be beneficial in the treatment of multi-
diseased bronchiectasis patients. Statins and macrolides have both been shown in randomised 
controlled trials to modify disease prognosis and improve clinical outcomes in bronchiectasis, 
owing to their anti-inflammatory effects; the development of new selective anti-inflammatory 
agents may hold promise for the future.26,27  
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A total of 81 different comorbidities were identified during the 5-year follow-up of these patients. 
As expected, not all comorbidities were equally prevalent and there were highly varying strengths 
of association with mortality. Healthcare providers are often limited in their assessment of patients 
due to time constraints and high patient numbers, therefore guidance that could identify 
comorbidities at highest risk of worse outcomes could optimise patient care. Our results show that, 
of the 81 comorbidities identified, 26 differed significantly between survivors and non-survivors. 
This is far higher than the 15 identified in the derivation of the CO-morbidity TEst (COTE) in 
COPD.28 The 13 comorbidities associated with the highest risk of death on multivariate analysis 
were incorporated into the BACI. Similar to those in COPD, these could constitute a core of “red 
flag” comorbidities that healthcare providers should pay increased attention to in guiding a targeted 
personalised screening and treatment approach in patients with bronchiectasis.28 Some, such as 
cardiovascular disease, pulmonary hypertension, cognitive impairment, and lung, oesophageal and 
hematological malignancies, are highly consistent with the little information relating to 
comorbidities in bronchiectasis that is currently available.4-7,10-12  However, the increased risk of 
death conferred by iron deficiency anemia, diabetes mellitus and peripheral vascular disease in this 
population is less well described. These findings therefore raise the possibility of a shared common 
biological pathway among these diseases, which requires further exploration. 
Although hypertension, high cholesterol and osteoporosis were in the top five most prevalent 
comorbidities, the direct risk of mortality conferred by these conditions was not significant. 
Whether this is because they are all treatable or they are risk factors for other potentially more 
harmful diseases, such as myocardial infarction, is unclear. However, selected solid tumors, such 
as lung and oesophageal cancer, conferred a significant increased risk of death with prevalence 
rates of 5% vs. 1% and 3.5% vs. 0.5% in non-survivors versus survivors (p=0.004 and p=0.01), 
respectively (Figure S2 in online supplement for breakdown of prevalence of solid tumors). 
Hematological malignancies, including lymphoma and leukemia, were also associated with a 
significantly increased mortality risk in this patient population. These findings have previously 
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been demonstrated in a nationwide cohort study of >53,000 bronchiectasis patients in Taiwan 
compared to >215,000 age and sex-matched controls whereby a 2.5 fold increased risk of lung 
cancer and a 2-fold increased risk of oesophageal and hematological malignancies was 
demonstrated.12 
A novel finding in this study was the relatively high prevalence of peripheral vascular disease (9%) 
and its strong independent association with risk of death, the mechanism of which remains unclear. 
Diabetes and iron deficiency anemia have both been described in COPD, the former possibly linked 
to overuse of inhaled corticosteroids in this patient population but more likely, both support the 
systemic inflammation hypothesis due to repeated infection, inflammation and chronic immune 
activation.25,29 Correction of anaemia could improve symptoms of fatigue and dyspnoea, thereby 
improving patients’ QoL and exercise capacity, reducing hospitalisations and improving overall 
survival. Anxiety and depression have been reported to be highly prevalent among bronchiectasis 
patients correlating with quality of life measures.8,9 In COPD, anxiety is an independent risk factor 
for mortality but no association of depression or anxiety with mortality was identified in this patient 
cohort.28 
This study confirms that patients with bronchiectasis are frequently afflicted by comorbidities 
which may drive disease, many of which confer an independent risk of death and may be missed 
unless specifically searched for. Although the data may be somewhat intuitive, our finding that 
COPD, inflammatory bowel disease, connective tissue diseases and asthma are associated with a 
higher mortality risk may inform decisions about which patients with bronchiectasis should be 
followed up more closely. Health care providers caring for these patients should routinely screen 
for the comorbidities outlined in the BACI because there may be effective interventions or changes 
in management that could reduce the risk of death. Further follow up studies are needed as with the 
development of any score to substantiate its utility, and determine how this score may impact 
clinical practice. It would also be interesting to further explore the relationship between high BACI 
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scores and lung or systemic inflammation in light of the association between higher exacerbations 
and Pseudomonas colonisation in co-morbid patients. 
The BACI is a quantitative risk stratification aetiology and comorbidity index for clinicians and 
researchers to quantify and prioritise comorbidities in bronchiectasis. Our data demonstrate that 
measurements of comorbidities as captured by the BACI improve the prognostic accuracy for 
mortality, particularly when used in conjunction with the BSI.19 The BACI captures diseases not 
included in the CCI and carries independent prognostic value relating to future disease outcomes 
such as future exacerbations, hospitalisations and Pseudomonas colonisation. Combining the BACI 
and BSI equips healthcare workers and researchers to better stratify patients and provides a 
platform for comparative effectiveness research. 
This study has several limitations: firstly, there is the potential for missed or as yet, undiagnosed 
comorbidities. For example, we experienced a somewhat lower prevalence of depression and 
anxiety in our cohort compared with studies that utilised the Hospital Anxiety and Depression 
Score to assess psychological wellbeing. However, in clinical practice, depression and anxiety are 
diagnosed upon history-taking and therefore this should not influence the results of the study. 
Similarly, there is no objective assessment for GORD, as we rely heavily on questionnaires for 
diagnosis in the clinical setting, often only resorting to the gold-standard 24h pH-impedance studies 
in refractory cases due to cost constraints. We may also have underestimated the prevalence of 
other conditions, such as pulmonary hypertension, in patients who had not had an adequate work-
up for the same but who may in fact, still have co-existing disease. There may have been variation 
between diagnostic criteria used in diagnosing comorbidities due to changes in guidelines 
throughout the study time period and variation in clinical practice between primary and secondary 
care and different healthcare institutions. 
Secondly, although a small number of patients in our derivation cohort had undergone transplant 
assessment, none of the patients in our derivation or validation cohorts had received a transplant 
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therefore we are unable to comment on the utility of the score in this patient population.30 
Comorbidity assessment is routine in the assessment of lung transplant candidates in order to 
determine suitability. The BACI score may highlight comorbidities that could negate transplant, 
e.g. in the case of metastatic malignancy, or perhaps delay transplant, e.g. with cases of iron 
deficiency anaemia where additional treatment may be needed beforehand. However, the BACI 
would not be considered in isolation in the assessment of transplant suitability and, as with any 
clinical prediction tool, it needs to be considered in the context of all other available information.  
Thirdly, with regards to our validation cohorts, we were unable to account for potential recruitment 
bias in the younger less co-morbid patients recruited to the original Brompton cohort of 19 years 
follow up compared to the Serbian cohort. Nevertheless, it is reassuring to see that the BACI works 
well in different cohorts among different healthcare systems. 
Finally, our derived score is relatively complex, awarding different points for each comorbidity. 
To aid calculation of the score, an online calculator is accessible at 
http:\\www.bronchiectasisseverity.com. This assigns a total on inputting the relevant data in 
sequential order and can therefore be completed in a very short space of time in the clinical setting. 
The BACI requires validation in US and developing countries to further substantiate its utility, and 
further studies determining how this score may impact clinical practice are now needed. In support 
of our findings, however, our large representative derivation cohort was made up of almost 1000 
patients of varying severity across different healthcare systems in four European countries, with 
external validation in two independent cohorts, one with 19-years follow-up and one from Eastern 
Europe, which should make these results generalisable to the majority of bronchiectasis clinics 
worldwide. 
 
Conclusions 
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Comorbidities in bronchiectasis are common and significantly contribute to disease burden and 
mortality. Surprising links with certain comorbidities may provide new insights into the underlying 
pathogenesis of this disease. We have derived a disease-specific bronchiectasis aetiology and 
comorbidity assessment tool for predicting future risk of mortality in bronchiectasis. Greater focus 
is needed to identify, assess and manage comorbidities in bronchiectasis in both clinical and 
research settings. Future interventions and treatment approaches should consider multiple 
comorbidities in these patients in order to maximise outcome and reduce the illness burden 
associated with this disease. 
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Figure legends: 
Figure 1 legend: Comorbidites in order of overall prevalence among survivor and non-survivor 
bronchiectasis patients. The figure also includes those comorbidities with a significantly higher 
prevalence in non-survivors compared with survivors regardless of their absolute prevalence 
(asterisk). Definitions of abbreviations: GORD: Gastro-oesophageal reflux disease; HTN: 
hypertension; COPD: Chronic obstructive pulmonary disease; CTD: Connective tissue disease; 
MI: myocardial infarction; CHF: Chronic heart failure; PVD: Peripheral vascular disease; 
CKD: Chronic kidney disease; CVA: Cerebrovascular attack; RA: Rheumatoid arthritis; 
ABPA: Allergic bronchopulmonary aspergillosis; TB: Tuberculosis; OSA: Obstructive sleep 
apnea. 
 
Figure 2 legend: (a) The performance of the Bronchiectasis Aetiology Comorbidity Index 
(BACI) in relation to the Bronchiectasis Comorbidity Index (BCI) without aetiologies and the 
widely validated Bronchiectasis Severity Index (BSI) using area under the receiver operator 
characteristic curve (AUC) scores. (b) The performance of the BACI in relation to the 
Comorbidity Count and the widely validated Charlson Comorbidity Index (CCI) using area 
under the receiver operator characteristic curve (AUC) scores. 
 
Figure 3 legend: The performance of the Bronchiectasis Aetiology Comorbidity Index (BACI) 
in predicting mortality, hospitalisations, exacerbation frequency and quality of life across all 
risk strata. All between group comparisons for mortality and hospitalisations were statistically 
significant at p<0.001. Between group comparisons for exacerbations were statistically 
significant at p=0.03. Correlation between the BACI and St George’s Respiratory 
Questionnaire (SGRQ) assessing quality of life was statistically significant at p<0.01. 
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Figure 4 legend: Kaplan-Meier survival curves representing survival probability at 5 years. (a) 
Kaplan-Meier survival curve according to the Bronchiectasis Severity Index (BSI) with mild 
(0-4 points), moderate (5-8 points) and severe (≥ 9 points). To demonstrate the predictive 
contribution of the Bronchiectasis Aetiology Comorbidity Index (BACI) to the BSI, the 
survival curves were represented for each BSI tertile (b) mild disease, (c) moderate disease, 
and (d) severe disease. BACI group 1 = score of O, BACI group 2 = score <6, BACI group 3 
= score ≥ 6. Survival is significantly lower in BACI groups 2 and 3 compared to group 1 which 
represents no high risk comorbidities. The gap between groups becomes much more evident as 
disease severity increases. 
 
 
Figure 5 legend:  Validation of the Bronchiectasis Aetiology Comorbidity Index (BACI) in two 
independent cohorts:  (a) Kaplan-Meier survival curves representing survival probability in 
BACI groups at 20 years in UK population, p=0.004; (b) Area under the receiver operator 
characteristic curve (AUC) score of BACI score in the Serbian cohort.
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Comorbidity paper tables 
Table 1: Derivation Cohort Patient Characteristics 
Patient characteristics Derivation Cohort (n=986) 
Demographic variables   
     Age, Years, Median (IQR)  67 (57-74) 
     Female, n (%) 589 (59.7) 
     Body Mass Index, Median (IQR) 24.6 (21.2-27.8) 
     Smokers / Ex-smokers, n (%) 379 (38.4) 
Clinical status   
     MRC, Median (IQR) 2 (1-3) 
     Exacerbations in the previous year, 
Median (IQR) 
2 (1-3) 
     At least one hospitalisation in the 
previous year, n (%) 
224 (22.7) 
Lung function   
     FEV1 % predicted, Median (IQR) 75 (54-95) 
Radiology status   
     Reiff score, Median (IQR) 4 (2-6) 
Microbiological status   
     Pseudomonas colonisation, n (%) 122 (12.4) 
    Other colonisation, n (%) 229 (25.3) 
Disease severity   
     BSI score, Median (IQR) 6 (4-10) 
     BSI 0-4 (mild), n (%) 312 (31.6) 
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     BSI 5-8 (moderate), n (%) 351 (35.6) 
     BSI ≥ 9 (severe), n (%) 323 (32.8) 
Comorbidities   
     No. of comorbidities, Median (IQR) 4 (2-6) 
     Range 0-20 
 
Definition of abbreviations: MRC: Medical Research Council dyspnoea score, FEV1%: forced 
expiratory volume in 1 second % predicted; BSI: Bronchiectasis Severity Index. 
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Table 2: Derivation of the Bronchiectasis Aetiology Comorbidity Index (BACI) and Point 
Allocation 
 
 
Definition of abbreviations: COPD: Chronic Obstructive Pulmonary Disease, RA: Rheumatoid 
arthritis. 
 
Comorbidity Hazard Ratio 95% CI P value Points 
Metastatic 
malignancy 
6.69 3.53-12.68 <0.0001 12 
Haematological 
malignancy 
2.85  1.17-6.97 0.02 6 
COPD 2.22  1.53-3.23 <0.0001 5 
Cognitive 
impairment 
2.21  0.82-6.01 0.12 5 
Inflammatory 
bowel disease 
2.01 0.75-5.40 0.17 4 
Liver disease 1.94  0.80-4.72 0.14 4 
Connective 
tissue disease 
1.78 1.19-2.68 0.005 3 
Iron deficiency 
anaemia 
1.78 0.80-2.68 0.16 3 
Diabetes 1.76 1.10-2.80 0.02 3 
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Asthma 1.65 1.00-2.73 0.050 3 
Pulmonary 
hypertension  
1.58 0.88-2.84 0.12 3 
Peripheral 
vascular disease 
1.50  1.00-2.25 0.052 2 
Ischaemic heart 
disease 
1.31 0.91-1.89 0.14 2 
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Table 3: Sensitivity and specificity values for derived clinical prediction tools 
 
 
 
 
 
 
 
Definition of abbreviations: BACI: Bronchiectasis Aetiology and Comorbidity Index; BCI Bronchiectasis Comorbidity Index; BSI: Bronchiectasis 
Severity Index 
 
 
 
Organisms PLR NLR Sensitivity Specificity PPV NPV 
BACI  
Grp 2 and 3 vs Grp 1 
Grp 3 vs Grp 1 and 2 
 
1.61 (1.47-1.75) 
3.80 (3.01-4.81) 
 
0.26 (0.16-0.42) 
0.54 (0.45-0.66) 
 
88.5 (81.5-93.6) 
53.3 (44.0-62.4) 
 
44.9 (41.6-48.3) 
86.0 (83.5-88.2) 
 
18.5 (15.4-21.9) 
34.9 (28.1-42.3) 
 
96.5 (94.2-98.1) 
92.9 (90.9-94.6)) 
BCI 
Grp 2 and 3 vs Grp 1 
Grp 3 vs Grp 1 and 2 
 
 
1.57 (1.42-1.74) 
 
4.68 (3.27-6.69) 
 
0.35 (0.23-0.53) 
0.73 (0.65-0.83) 
 
 
83.6 (75.8-89.7) 
 
32.0 (23.8-41.0) 
 
 
46.9 (43.5-50.3) 
 
93.2 (91.3-94.8) 
 
 
18.2 (15.1-21.6) 
 
39.8 (30.0-50.2) 
 
 
95.3 (92.8-97.1) 
 
90.7 (88.6-92.5) 
BSI       
Mod/severe vs mild 
Severe vs Mod/mild 
1.37 (1.26-1.48) 
2.18 (1.83-2.59) 
0.31 (0.18-0.52) 
0.53 (0.42-0.67) 
89.3 (82.5-94.2) 
62.3 (53.1) 
34.6 (31.4-37.9) 
71.4 (68.3-74.4) 
16.2 (13.5-19.2) 
23.5 (19.0-28.5) 
95.8 (92.9-97.8) 
93.1 (90.9-94.9) 
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Table 4: Correlation of the BACI with clinical scores and severity indices 
Patient characteristics (n=986) Spearman’s Rho P value 
BSI 0.23 <0.0001 
FACED 0.24 <0.0001 
Age 0.20 <0.0001 
Male gender 0.20 <0.0001 
Smoking history 0.33 <0.0001 
Reiff radiological score 0.08 0.008 
MRC dyspnoea score 0.31 <0.0001 
LTOT 0.23 <0.0001 
Prior exacerbations 0.12 0.0002  
Prior hospitalisations 0.13 <0.0001 
FEV1 % -0.26 <0.0001 
Pseudomonas colonisation 0.078 0.01 
Exacerbations on follow-up 0.11 0.0006 
Hospitalisations on follow-up 0.22 <0.0001 
 
Definition of abbreviations: BSI: Bronchiectasis Severity Index, FACED: Acronym for a 5-
component disease severity score; MRC: Medical Research Council, LTOT: long term oxygen 
therapy, FEV1%: Forced expiratory volume in 1 second % predicted.  
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Online supplementary data 
Study Title: 
Comorbidities and the risk of mortality in patients with bronchiectasis: an international 
cohort study 
 
Material contained in this document: 
 Process to define bronchiectasis aetiologies 
 Data collection procedure at each site 
 Standardised definitions of comorbidities 
 Guide to interpretation of Spearman’s rho correlation coefficient 
 Table S1: Comorbidities prevalence for the full cohort and prevalence comparison 
between survivors and non-survivors 
 Figure S1: Solid tumour prevalence chart 
 Table S2: Derivation of the bronchiectasis comorbidity index (BCI) 
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Process to define bronchiectasis aetiologies 
Patients in each site underwent the same comprehensive diagnostic work-up as suggested by 
the 2010 British Thoracic Society (BTS) guidelines including: full blood count, serum 
electrophoresis, serum immunoglobulin (Ig) G, IgA, IgM, total IgE, specific IgE and precipitins 
for A. fumigatus, and pulmonary function testing with reversibility testing and diffusion 
capacity test.18 If there was a clinical suspicion of primary ciliary dyskinesia, such as recurrent 
sinusitis and/or chronic otitis media, patients were referred for further testing with nasal 
mucociliary clearance measured by the saccharin test and/or nasal nitric oxide at specialist 
primary ciliary dyskinesia centres. Alpha1-antitripsin deficiency was evaluated in the presence 
of emphysema affecting lower lobes on high-resolution computed tomography (HRCT) scan 
and/or significant family history. Autoimmunity testing including anti-nucleolar antibodies, 
extractable nuclear antigens, anti-neutrophil cytoplasmic antibodies, rheumatoid factor and 
anti–citrullinated protein antibody were requested if a rheumatological disease was clinically 
suspected. Sweat test and cystic fibrosis (CF) transmembrane conductance regulator genetic 
testing were requested if there were signs and symptoms suggestive for CF as suggested by 
BTS guidelines.18 
An evaluation of CT images and testing results was performed, including immunoglobulins, 
skin prick testing or serum IgE resting to A. fumigatus and Aspergillus precipitins, and serum 
electrophoresis, in order to differentiate patients into categories of congenital abnormalities, 
post-obstructive bronchiectasis, primary or secondary immunodeficiency, alpha1-antitrypsin 
deficiency or allergic bronchopulmonary aspergillosis (ABPA). If all of the above tests were 
negative, a history of prior severe respiratory infections was investigated, including previous 
infection with tuberculosis or non-tuberculous mycobacteria. If no history of previous 
respiratory infections was present, an association between bronchiectasis and other diseases, 
such as COPD, asthma, inflammatory bowel disease (IBD), overt aspiration on barium studies 
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or connective tissue disease (CTD) was investigated. If tests were negative and no association 
with other diseases was found, a diagnosis of idiopathic bronchiectasis was made.  
A serum IgE of >1000 IU/ml, positive Aspergillus precipitins and skin prick, blood eosinophilia 
of >0.4 and compatible radiology was required to fulfil the diagnosis of ABPA.31 Post-infective 
bronchiectasis (PIB) was diagnosed in patients reporting a history of symptom onset within 5 
years of a severe respiratory tract infection, such as pneumonia, whooping cough or 
complicated measles infection. Where a patient reported a history of severe respiratory 
infections, but with a five-year symptom free period, the post-infective diagnosis was not 
attributed. Post- tuberculous bronchiectasis was diagnosed in patients with clearly documented 
prior tuberculosis and compatible radiology. COPD-associated bronchiectasis was classified in 
the presence of significant smoking history and airflow obstruction according to GOLD 
criteria.32 Bronchiectasis associated with asthma was diagnosed in patients without post-
infective bronchiectasis and with normal or negative results of blood investigations, according 
to GINA guidelines.33 Bronchiectasis associated with IBD was diagnosed if patients had 
ulcerative colitis or Crohn’s disease and no other suggested aetiology for bronchiectasis. In the 
presence of a diagnosis of both bronchiectasis and CTD, including rheumatoid arthritis, 
Sjögren’s syndrome, systemic sclerosis, psoriatic arthritis, ankylosing spondylosis or mixed 
CTD, a diagnosis of CTD-associated bronchiectasis was made. Yellow nail syndrome was 
diagnosed when examination showed yellow discoloration of dystrophic nails together with 
bronchiectasis and sinusitis, whether or not patients had other features of the syndrome. 
Young’s syndrome was diagnosed when there was a history of bronchiectasis, sinusitis and 
azoospermia in males and negative CF testing.34 A diagnosis of IB was made by exclusion of 
any known cause. 
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Data collection 
Demographics, comorbidities, disease severity, bronchiectasis aetiology, symptoms, sputum 
evaluation, baseline radiological, functional and laboratory findings, quality of life, and long-
term treatments and outcomes - including exacerbations, hospitalisations and mortality - over 
a five-year follow-up period were recorded in each site. Radiological severity was assessed 
using the modified Reiff score incorporating number of lobes and degree of dilatation as 
previously described.16 Bronchiectasis severity was evaluated according to the BSI.16 Quality 
of life was assessed using the St. George’s Respiratory Questionnaire (SQRQ).35 
Microbiological examinations were performed on sputum, bronchial aspiration or 
bronchoalveolar lavage during stable state. Identification of microorganisms and susceptibility 
testing were performed according to standard methods. Chronic infection was defined by the 
presence of pathogenic bacteria in sputum culture on two or more occasions at least three 
months apart over a one-year period.36 The predominant pathogen was the organism grown 
most frequently over the study period. Patients who were unable to provide sputum samples 
due to absence of a productive cough were classified as not having chronic infection for the 
purposes of analysis. 
Study outcomes 
Exacerbations: An exacerbation of bronchiectasis was defined as a clinical diagnosis of 
exacerbation for which antibiotics were prescribed in the presence of at least one (and usually 
more than one) of the following symptoms: increasing cough, increasing sputum volume, 
worsening sputum purulence, worsening dyspnea, increased fatigue/malaise, fever, and 
hemoptysis.18  
Hospitalization for severe exacerbations: Severe exacerbations were defined according to the 
BTS guidelines, and unscheduled hospitalizations or emergency department visits for severe 
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bronchiectasis exacerbations or complications were recorded from patient histories and verified 
using administrative databases that record admissions.16,18  
Mortality: All-cause mortality up to 5 years of follow up was evaluated. 
 
Details of each individual cohort are displayed below: 
Dundee, United Kingdom 
This cohort consisted of 286 consecutive bronchiectasis patients attending a specialist 
bronchiectasis clinic in Tayside, Scotland, UK. Patients in this cohort were included in 2011 
with follow-up data to September 2015. Patients were assessed according to a standardised 
protocol based on the British Thoracic Society (BTS) guidelines including standardised testing 
for aetiology. Clinic data were recorded at baseline and subsequent clinic review. All 
bacteriology was performed on early morning sputum samples. Patients were routinely asked 
to provide sputum samples at least twice a year at clinic reviews. Data on exacerbations were 
obtained from patient histories and verified against electronic general practice prescribing data 
to ensure all exacerbations treated with antibiotics were captured. Hospital admissions and 
mortality data were obtained from patient follow-up and verified by electronic medical records 
containing all hospital admissions and deaths regionally. Follow-up status was verified in 100% 
of participants. Outcomes available in this database were 5-year mortality, subsequent hospital 
admissions and exacerbations, and quality of life data. 
Galway, Ireland 
This database included 280 consecutive patients attending respiratory clinics at Galway 
University Hospitals and Merlin Park University Hospitals in Galway, Ireland. Patients in this 
cohort were included in 2009-2011 with follow-up data to September 2015. All patients 
undergoing diagnostic investigation for bronchiectasis were assessed according to BTS 
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guidelines including standardised testing for aetiology. In this centre, all patients referred for 
investigation routinely undergo bronchoscopic evaluation and lavage as part of their work-up. 
Clinic data were recorded at baseline and subsequent review. Patients were asked to provide 6-
mpnthly samples of sputum where possible for microbiological surveillance. Data on 
exacerbations, hospitalisations and mortality were obtained from patient histories and full 
review of medical and electronic records. Data on exacerbations and hospitalisations was 
verified against prescribing practices and admission records. Data pertaining to mortality and 
causes of death were verified against the Health Service Executive Civil Register. Follow-up 
status was verified in 100% of participants. Outcomes available in this database were 5-year 
mortality, subsequent hospital admissions and exacerbations. 
Leuven, Belgium 
The bronchiectasis cohort from the University of Leuven, Belgium, contains data on 190 
patients seen at the department with a radiological and clinical diagnosis of bronchiectasis from 
June 2006 to October 2012. All patients had a high resolution CT scan confirming the presence 
of bronchiectasis. Patients underwent testing for aetiological causes in accordance with British 
Thoracic Society guidelines. Clinical data were collected at baseline and survival data 
determined for a mean of 49 months. The definitions of colonisation and the assessments of 
radiological severity were in accordance with those used in the other derivation cohorts. 
Outcomes available in this cohort were 5-year mortality, subsequent hospital admissions and 
exacerbation frequency. 
Monza, Italy 
This cohort included 230 consecutive patients with bronchiectasis (defined by clinical history 
and high-resolution computed tomography scan) attending respiratory clinics at the San 
Gerardo Hospital in Monza, Italy. Patients in this cohort were included in 2011 and 2012 with 
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follow up data to September 2015. As with other cohorts, patients with cystic fibrosis or 
traction bronchiectasis secondary to pulmonary fibrosis were excluded. Patients were assessed 
according to a standardised protocol based on BTS guidelines including standardised testing 
for aetiology. Data on exacerbations, hospital admissions and mortality were obtained from 
patient histories and follow-up. Follow-up status was verified in 100% of participants. 
Outcomes available in this cohort were 5-year mortality, subsequent hospital admissions and 
exacerbation frequency. 
 
Comorbidity assessment 
Comorbidity assessment was performed according to standardized definitions with review of 
objective assessment and confirmatory tests to verify diagnosis where possible. Below are a 
few examples of how comorbidity was determined in the most prevalent or significant 
comorbidities among this patient population. 
Gastro-esophageal reflux disease (GERD): Based on a presumptive diagnosis of GERD in the 
setting of typical symptoms of heartburn and regurgitation or by improvement in symptoms 
after trial of therapy as per American College of Gastroenterology recommendations. Patients 
were considered to have GERD where a diagnosis of GERD was recorded in the notes by a 
primary or secondary care physician, or in a patient taking a prescribed anti-reflux medication. 
Hypertension: Based on previous guidelines of clinic blood pressure readings of 
>140/90mmHg on three separate occasions taking the lowest of at least two readings at each 
visit. Note: since 2011 guidelines, ambulatory and/or home blood pressure measurements are 
included in the diagnosis of arterial hypertension according to the British Hypertension and 
European Society of Cardiology guidelines. Patients were considered to have hypertension 
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where a diagnosis of hypertension was recorded in the notes by a primary or secondary care 
physician, or in a patient taking a prescribed anti-hypertensive medication. 
High cholesterol: Based on an objective fasting total cholesterol level of >5 mmol/L for healthy 
adults and/or >4 mmol/L in high risk patients and/or a ratio of total cholesterol to HDL above 
4.The 2014 guidelines allow measurement of cholesterol in non-fasting samples. Patients were 
considered to have high cholesterol where a diagnosis of high cholesterol was recorded in the 
notes by a primary or secondary care physician AND objective evidence of cholesterol levels 
could be assessed, or in a patient taking a prescribed cholesterol medication for primary or 
secondary prevention. 
COPD: Based on the presence of a significant smoking history of >10 pack years and objective 
confirmation of airflow obstruction according to GOLD criteria. Patients were considered to 
have COPD where a diagnosis of COPD was recorded in the notes in patients with a significant 
smoking history AND objective evidence of airflow obstruction in primary or secondary care. 
In patients prescribed inhaled medications without objective evidence of airflow limitation, a 
diagnosis of COPD was not recorded. 
Osteoporosis: Based on a bone mineral density that is 2.5 SD or more below that of a “young 
normal” adult (T-score at or below -2.5) on DEXA scanning and/or clinical diagnosis in at-risk 
individuals who have sustained a low-trauma fracture according to World Health Organization 
guidelines. Patients were considered to have osteoporosis where a diagnosis of osteoporosis 
was recorded in the notes by a primary or secondary care physician AND objective evidence 
on DEXA scanning or in patients taking bisphosphonate treatment. 
Connective tissue disease: Based on assessment by an expert rheumatologist according to 
American College of Rheumatology guidelines incorporating history, physical examination, 
laboratory and radiographic findings according to individual disease. 
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Myocardial infarction: Based on a rise and/or fall of cardiac biomarker values plus at least one 
of: symptoms of ischemia, new or presumed new significant ST-segment–T wave (ST–T) 
changes or new left bundle branch block (LBBB), development of pathological Q waves in the 
ECG, imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality and/or identification of an intracoronary thrombus by angiography or autopsy 
according to the universal definition in the European Cardiac Society guidelines. Patients were 
considered to have had a myocardial infarction where a diagnosis was recorded in the notes 
AND objective evidence in the form of blood tests, ECG or imaging studies was available. 
Chronic heart failure: Based on the presence of symptoms and signs of heart failure with 
measurement of ejection fraction on echocardiography to determine if reduced or preserved 
and to determine the presence of structural heart disease or diastolic dysfunction in the presence 
of a preserved ejection fraction according to the European Society of Cardiology guidelines. 
Patients were considered to have heart failure where a diagnosis of heart failure was recorded 
in the notes or patients were prescribed heart failure medications AND objective evidence on 
echocardiography was available. 
Depression: Based on the presence of at least four out of ten depressive symptoms, present for 
at least 2 weeks for most of every day according to ICD-10 criteria. Patients were considered 
to have depression where a diagnosis of depression was recorded in the notes by primary or 
secondary care physicians or in patients prescribed anti-depressant medications. 
Solid tumor/metastatic malignancy: Based on assessment by an expert physician and/or 
oncologist with appropriate objective staging imaging and histopathological investigations. 
Peripheral vascular disease: Based on the presence of symptoms and signs of peripheral 
vascular disease, objective measurement of ankle brachial pressure indices in primary care 
setting or confirmatory imaging investigations such as Doppler ultrasound, angiography or 
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digital subtraction arteriography according to European Society of Cardiology guidelines. 
Patients were considered to have peripheral vascular disease where a diagnosis of peripheral 
vascular disease was recorded in the notes AND objective evidence was available. 
Atrial fibrillation: Based on an irregular heart rate with ECG confirmation. Patients were 
considered to have atrial fibrillation where a diagnosis of atrial fibrillation was recorded in the 
notes by a primary or secondary care physician AND objective ECG evidence was available. 
Chronic kidney disease: Based on objective reduced eGFR values for staging of chronic kidney 
disease as per national and international guidelines. 
Diabetes mellitus: Based on plasma glucose criteria, with fasting glucose >7.0 mmol/L, random 
or 2-h glucose post-oral glucose tolerance test > 11.1 mmol/L, or HbA1C ≥6.5% according to 
the American Diabetes Association guidelines. Patients were considered to have diabetes 
mellitus where a diagnosis of diabetes mellitus was recorded in the notes by a primary or 
secondary care physician AND objective blood glucose levels were available. 
Cerebrovascular accident/Transient ischemic attack: Based on the presence of symptoms and 
signs with confirmatory imaging findings on CT brain, MRI brain, Doppler USS neck or other 
investigations according to the American Heart Association/ American Stroke Association 
guidelines. Patients were considered to have a CVA/TIA where a diagnosis was recorded in 
the notes, patients were prescribed anticoagulant medications AND objective evidence on 
imaging was available. 
Rheumatoid arthritis: Based on assessment by an expert rheumatologist according to American 
College of Rheumatology guidelines incorporating history, physical examination, laboratory 
and radiographic findings with four of seven of the diagnostic criteria present, one of which 
must have been present for a minimum of 6 weeks.  
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Pulmonary hypertension: Based on an increase in mean pulmonary arterial pressure ≥25 mmHg 
at rest as assessed by right heart catheterization or echocardiography. Patients were considered 
to have pulmonary hypertension where a diagnosis was recorded in the notes AND objective 
evidence on imaging was available. 
Thromboembolic disease: Based on objective confirmation of deep vein thrombosis on 
Doppler ultrasound or pulmonary embolism on CTPA. Patients were considered to have 
thromboembolic disease where a diagnosis was recorded in the notes, patients were prescribed 
anticoagulant medications AND objective evidence on imaging was available. 
Overt aspiration: Based on objective confirmation of aspiration on barium swallow studies. 
Patients were considered to have overt aspiration where a diagnosis was recorded in the notes 
AND objective evidence on imaging was available. 
Leukemia: Based on assessment by an expert oncologist according to World Health 
Organization guidelines incorporating history, physical examination, full blood count and film, 
imaging, bone marrow biopsy and cytogenetic abnormality conformation. 
Lymphoma: Based on assessment by an expert oncologist according to World Health 
Organization guidelines incorporating history, physical examination, full blood count and film, 
imaging and histopathological confirmation. 
Iron deficiency anemia: Based on objective low iron stores and a hemoglobin level two 
standard deviations below normal as per national and international guidelines.  
Cognitive impairment: Based on a clinical diagnosis by a primary or secondary care physician 
whereby acquired cognitive deficits in more than one area of cognition interfere with normal 
activities of daily living and represent a decline from a previously higher level of functioning. 
Patients were considered to have cognitive impairment where a diagnosis was recorded in the 
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notes, deficits on structured memory tests were noted, and/or patients were prescribed 
medications to treat dementia. 
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Guide to interpretation of Spearman’s rho correlation coefficient 
Interpretation of Spearman’s rho correlation coefficient: Spearman’s correlation coefficient is 
a statistical measure of the strength of the relationship between paired data. The closer the value 
is to 1, the stronger the relationship. Correlation is an effect size; the strength of the correlation 
can therefore be described using the following guide for the absolute value Spearman’s rho: 
≤0.19 - very weak; 0.2-0.4 weak; 0.40-0.59 moderate; 0.60-0.79 strong; ≥ 0.80 very strong. 
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Table S1: Comorbidities prevalence for the full cohort and prevalence comparison 
between survivors and non-survivors. 
 Comorbidity 
prevalence 
Total cohort 
(n=986) % 
Survivors  
(n=864) % 
Non-survivors 
(n=122) % 
P value 
1 *GERD 34.3 32.4 47.6 0.001 
2 HTN 27.5 26.5 34.4 0.080 
3 High cholesterol 20.1 19.6 23.8 0.281 
4 *COPD 17.1 14.2 37.7 <0.001 
5 Osteoporosis 15.9 15.2 20.5 0.147 
6 Rhinosinusitis 13.1 13.5 9.8 0.315 
7 Asthma 12.4 12.5 11.5 0.883 
8 *CTD 12 10.9 19.7 0.010 
9 *MI 11.7 10.3 21.3 0.001 
10 *CHF 10 8.7 19.7 <0.001 
11 Depression 9.3 9.1 10.7 0.496 
12 *Solid tumour 9.1 8.7 12.3 0.028 
      *Lung cancer 1.4 0.9 4.9 0.004 
      *Oesophageal cancer 0.8 0.5 3.3 0.010 
13 *PVD 8.9 6.8 23.8 <0.001 
14 *PUD 8.9 6.8 23.8 <0.001 
15 *Atrial fibrillation 8.7 7.6 16.4 0.003 
16 Anxiety 8.4 8.2 9.8 0.372 
17 *CKD 8.2 6.8 18.1 <0.001 
18 *Diabetes Mellitus 7.1 6.0 14.8 0.002 
19 Immunodeficiency 6.8 6.7 7.4 0.704 
20 *CVA 6.1 5.2 12.3 0.007 
21 ABPA 5.8 6.1 3.3 0.298 
22 *RA 5.7 4.9 11.5 0.007 
23 Osteoarthritis 5.6 5.6 9 0.151 
24 Thyroid disorder 5.6 5.9 4.9 0.836 
25 *Pulmonary HTN 4.4 3.5 10.7 0.001 
26 TB 4.1 3.8 6.6 0.151 
27 Childhood infection 4 3.9 4.1 0.808 
28 Valvulopathy 3.5 3.1 6.6 0.066 
29 *Thromboembolic 
disease 
3.4 2.9 6.6 0.028 
30 Liver disease 3.4 3.5 3.3 1.000 
31 Sarcoidosis 2.5 2.7 0.8 0.346 
32 IBD 2.4 2.4 2.5 1.000 
33 Morbid obesity 2.3 2.1 4.1 0.191 
34 Overt aspiration 1.9 1.8 2.5 0.721 
35 *Psoriasis 0.7 0.5 2.5 0.045 
36 *Metastatic malignancy 1.8 0.9 8.2 <0.001 
37 Spinal problems 1.8 1.5 4.1 0.061 
38 OSA 1.6 1.6 1.6 1.000 
39 Pulmonary nodules 1.5 1.6 0.8 0.710 
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40 *TIA 1.5 1 4.9 0.006 
41 *Leukaemia 1.4 1.1 3.3 0.021 
42 BPH 1.4 1.0 2.5 0.177 
43 PCD 1.3 1.5 0 0.388 
44 *Iron deficiency anaemia 1.3 0.9 4.1 0.015 
45 Gout 1.3 1.2 2.5 0.211 
46 Cataracts 1.3 1.3 1.6 0.669 
47 *Cognitive impairment 1.1 0.8 2.6 0.010 
48 *Lymphoma 1.1 0.4 2.6 0.006 
49 Vasculitis 1.1 1 1.7 0.635 
50 PMR 1.1 1.2 0.8 1.000 
51 Recurrent cystitis 1.1 0.9 2.5 0.145 
52 A1AT deficiency 1 1.2 0 0.621 
53 Diverticular disease 1 0.8 2.5 0.116 
54 Gallstones 0.9 1 0 0.611 
55 Congenital disorders 0.8 0.8 0.8 1.000 
56 Other psychological 
disorder 
0.6 0.7 0 1.000 
57 Epilepsy 0.6 0.5 1.6 0.163 
58 Postural hypotension 0.6 0.5 1.6 0.163 
59 *Multiple myeloma 0.6 0.3 2.5 0.028 
60 Coeliac disease 0.5 0.3 1.7 0.118 
61 Pernicious anaemia 0.5 0.3 1.6 0.118 
62 Parkinson’s disease 0.5 0.4 0.9 0.484 
63 Pneumothorax 0.4 0.2 1.6 0.077 
64 Hemochromatosis 0.4 0.5 0 1.000 
65 Fibromyalgia 0.4 0.2 1.6 0.077 
66 Primary renal disease 0.4 0.2 1.6 0.077 
67 Migraine 0.4 0.3 0.8 0.411 
68 Other neurological 
disorders 
0.4 0.2 1.6 0.077 
69 Glaucoma 0.4 0.3 0.8 0.411 
70 Haemangioma 0.4 0.5 0 1.000 
71 AIDS 0.2 0 0.2 1.000 
72 Cardiomyopathy 0.2 0.1 0.8 0.232 
73 *AAA 0.2 0 1.6 0.015 
74 Ovarian problems 0.2 0.2 0 1.000 
75 Syphilis 0.2 0.2 0 1.000 
76 Asbestosis 0.1 0.1 0 1.000 
77 Spinal muscular atrophy 0.1 0.1 0 1.000 
78 Myasthenia gravis 0.1 0.1 0 1.000 
79 Pancreatitis 0.1 0.1 0 1.000 
80 Tracheomalacia 0.1 0.1 0 1.000 
81 Swyer James Macloud 0.1 0.1 0 1.000 
 
Definition of abbreviations: GERD: gastro-oesophageal reflux disease; HTN: hypertension; 
COPD: chronic obstructive pulmonary disease;  CTD; connective tissue disease; MI: 
46 
 
myocardial infarction; CHF: congestive heart failure; PVD: peripheral vascular disease; PUD: 
peptic ulcer disease;  CKD: chronic kidney disease;  CVA: cerebrovascular attack; ABPA: 
allergic bronchopulmonary aspergillosis; RA: rheumatoid arthritis; TB: tuberculosis; IBD: 
inflammatory bowel disease; OSA: obstructive sleep apnoea; TIA: transient ischaemic attack; 
BPH: benign prostatic hyperplasia; PCD: primary ciliary dyskinesia; PMR: polymyalgia 
rheumatica; A1AT: Alpha-1 anti-trypsin deficiency; AIDS: acquired immunodeficiency 
syndrome; AAA: abdominal aortic aneurysm. 
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Figure S1: Solid tumour prevalence chart 
Solid tumours were identified in 90 (9.1%) of total cohort. This pie chart provides a breakdown 
of the prevalence of tumor type among these patients. 
 
Definition of abbreviations: ENT = Ears, nose and throat cancers. 
*Represents statistically significant difference between survivors and non-survivors. 
~Represents female-specific malignancies. ^Represents male-specific malignancies. 
 
 
14
10
8
8
8
7
6
6
6
3
2
2
2
2
2 2
1 1
Lung*
Breast~
Oesophageal*
Prostate^
Bladder
Skin
Gastric
Endometrial~
Colorectal
Renal
Neurological
Liver
Thyroid
Thymoma
ENT
Pancreatic
48 
 
Table S2: Derivation of the Bronchiectasis Comorbidity Index (BCI) and Point Allocation 
 
Comorbidity Hazard Ratio 95% CI P value Points 
Metastatic 
malignancy 
5.21  2.83-9.58 <0.0001 10 
Iron deficiency 
anaemia 
2.52 1.15-5.55 0.02 6 
Liver disease 2.21 0.91-5.37 0.08 5 
Haematological 
malignancy* 
1.87 0.79-4.45 0.16 4 
Diabetes 
mellitus 
1.77 1.13-2.79 0.01 3 
Solid tumour 1.60 1.00-2.57 0.048 3 
Pulmonary 
hypertension 
1.56 0.87-2.80 0.14 3 
Peptic ulcer 
disease 
1.49 0.85-2.59 0.16 2 
Peripheral 
vascular 
disease 
1.44 0.97-2.15 0.07 2 
GORD 1.31 0.96-1.79 0.09 2 
IHD 1.31 0.91-1.87 0.14 2 
 
*Although haematological malignancy can be a cause of bronchiectasis, we retained this in the 
model where haematological malignancy was not considered by the clinician as the underlying 
aetiology after testing.
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